Mostrar el registro sencillo del ítem
dc.contributor.author | Flores Montero, Juan Alejandro | |
dc.contributor.author | Sanoja Flores, Luzalba | |
dc.contributor.author | Paiva, Bruno | |
dc.contributor.author | Puig Morón, Noemí | |
dc.contributor.author | García Sánchez, Omar | |
dc.contributor.author | Böttcher, Sebastian | |
dc.contributor.author | van der Velden, VHJ | |
dc.contributor.author | Pérez Morán, José | |
dc.contributor.author | Vidriales Vicente, María Belén | |
dc.contributor.author | García Sanz, Ramón | |
dc.contributor.author | Jiménez, C. | |
dc.contributor.author | González Díaz, Marcos | |
dc.contributor.author | Martínez-López, J. | |
dc.contributor.author | Corral-Mateos, A. | |
dc.contributor.author | Grigori, G.E. | |
dc.contributor.author | Fluxá, R. | |
dc.contributor.author | Pontes, R. | |
dc.contributor.author | Caetano, J. | |
dc.contributor.author | Sedek, L. | |
dc.contributor.author | Cañizo Fernández-Roldán, María Consuelo del | |
dc.contributor.author | Bladé, Joan | |
dc.contributor.author | Huerta, Juan José la | |
dc.contributor.author | Aguilar, Carlos | |
dc.contributor.author | Bárez, Abelardo | |
dc.contributor.author | García-Mateo, A. | |
dc.contributor.author | Labrador Gómez, Jorge | |
dc.contributor.author | Leoz, P. | |
dc.contributor.author | Aguilera-Sanz, C. | |
dc.contributor.author | San Miguel, Jesús F | |
dc.contributor.author | Mateos Manteca, María Victoria | |
dc.contributor.author | Durie, Brian | |
dc.contributor.author | van Dongen, J.J.M. | |
dc.contributor.author | Orfao de Matos Correia e Vale, José Alberto | |
dc.date.accessioned | 2018-02-06T08:06:44Z | |
dc.date.available | 2018-02-06T08:06:44Z | |
dc.date.issued | 2017-10 | |
dc.identifier.citation | Leukemia. 2017 Oct;31(10):2094-2103 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10366/136897 | |
dc.description.abstract | [EN]Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics. | es_ES |
dc.description.sponsorship | This work has been supported by the International Myeloma Foundation-Black Swan Research Initiative, the Red Temática de Investigación Cooperativa en Cáncer (RTICC); grant SA079U14 from the Consejería de Educación, Junta de Castilla y León, Valladolid, Spain and; grant DTS15/00119 from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain. | es_ES |
dc.format.mimetype | application/pdf | |
dc.language.iso | eng | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Unported | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ | |
dc.subject | Oncology | es_ES |
dc.subject | Next generation flow | es_ES |
dc.subject | Multiple myeloma | es_ES |
dc.subject | Minimal residual disease | es_ES |
dc.title | Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.1038/leu.2017.29 | |
dc.relation.projectID | SA079U14 from the Consejería de Educación, Junta de Castilla y León, Valladolid, Spain | es_ES |
dc.relation.projectID | DTS15/00119 from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid, Spain | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |